Retractable Technologies (NYSE:RVP) is a medical device company specializing in the design, development and marketing of safety-engineered syringes and intravenous catheter systems. The company’s flagship offerings include retractable syringe technologies that automatically withdraw and encapsulate the needle following use, effectively reducing the risk of needlestick injuries to healthcare workers and patients. In addition to its core syringe line, Retractable Technologies provides safety-based I.V. catheter systems and safety needle devices designed to integrate seamlessly into existing clinical workflows.
Retractable Technologies’ products are built around proprietary needle retraction mechanisms that meet stringent regulatory standards, including FDA clearance in the United States and CE marking for European markets. Key product families include the INNOLET® and SoloShot® safety syringes, which incorporate user-activated or automatic retraction features, as well as a series of safety I.V. catheters featuring passive needle retraction. These devices are widely used across acute care hospitals, outpatient clinics and long-term care facilities, where they help organizations comply with evolving needlestick safety regulations and best practices.
Headquartered in Little Elm, Texas, Retractable Technologies was founded in the late 1990s and became a publicly traded company on the NYSE American exchange under the ticker RVP in the early 2000s. Over the years, the company has expanded its geographic footprint through direct sales operations in North America and strategic distributor partnerships in Europe, Latin America and parts of Asia. Manufacturing and quality control processes are conducted in cGMP-compliant facilities, ensuring consistent product performance and adherence to international safety standards.
Under the leadership of Chief Executive Officer Alan J. Davis and a seasoned management team with extensive experience in medical device innovation, Retractable Technologies continues to invest in research and development aimed at broadening its product portfolio and enhancing device ergonomics. The company’s ongoing collaborations with healthcare institutions and industry consortia support clinical studies, user training programs and advocacy initiatives that underscore the importance of sharps safety in modern healthcare delivery.
